You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

CLINICAL TRIALS PROFILE FOR TIPIFARNIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Tipifarnib

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00003707 ↗	Combination Chemotherapy in Treating Patients With Advanced Cancer	Completed	National Cancer Institute (NCI)	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining R115777 with gemcitabine in treating patients with advanced cancer.
NCT00003707 ↗	Combination Chemotherapy in Treating Patients With Advanced Cancer	Completed	The University of Texas Health Science Center at San Antonio	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining R115777 with gemcitabine in treating patients with advanced cancer.
NCT00004009 ↗	R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or recurrent acute leukemia or chronic myelogenous leukemia.
NCT00004009 ↗	R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia	Completed	University of Maryland Greenebaum Cancer Center	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or recurrent acute leukemia or chronic myelogenous leukemia.
NCT00004009 ↗	R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia	Completed	University of Maryland, Baltimore	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or recurrent acute leukemia or chronic myelogenous leukemia.
NCT00005041 ↗	R115777 in Treating Patients With Relapsed Small Cell Lung Cancer	Completed	National Cancer Institute (NCI)	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed small cell lung cancer.
NCT00005041 ↗	R115777 in Treating Patients With Relapsed Small Cell Lung Cancer	Completed	New York University School of Medicine	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed small cell lung cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Tipifarnib

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Leukemia	8
Untreated Adult Acute Myeloid Leukemia	8
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)	7
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Leukemia	27
Leukemia, Myeloid	22
Leukemia, Myeloid, Acute	19
Leukemia, Myelomonocytic, Acute	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Tipifarnib

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	356
Spain	15
United Kingdom	8
Canada	6
Germany	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	22
New York	22
Texas	22
Florida	18
Maryland	17
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Tipifarnib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	3
Phase 2/Phase 3	1
Phase 2	46
[disabled in preview]	35
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	68
Recruiting	8
Terminated	5
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tipifarnib

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
National Cancer Institute (NCI)	63
Kura Oncology, Inc.	8
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	7
[disabled in preview]	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
NIH	65
Other	39
Industry	21
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.